Xenetic Biosciences Inc (XBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.49M
Last updated: Nov 17, 2026 at 4:10 PM ET
Xenetic Biosciences Inc (XBIO) Statistics
Xenetic Biosciences (XBIO) has a market cap of $3.49M. Its share count is up 51.94% from a year earlier. It holds $5.81M more cash than debt, 166.40% of its market cap.
Total Valuation
| Market Cap | $3.49M |
|---|---|
| Latest price (Nov 17, 2026) | $1.54 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.2x and 0.8x. Its year-end P/S ranged from 1.2x to 43.2x from 2017 to 2025.
| P/S Ratio | 1.2x |
|---|---|
| P/B Ratio | 0.8x |
Price Statistics
The stock is down 40.77% over 52 weeks and trades 33.04% below its 50-day average.
| Beta (1Y) | 1.55 |
|---|---|
| 52-Week Change | -40.77% |
| 1-Month Change | -20.21% |
| 3-Month Change | -54.17% |
| 6-Month Change | -46.90% |
| 5-Year Change | -87.72% |
| 10-Year Change | -99.63% |
| Total Return (1Y) | -40.77% |
| Total Return (3Y CAGR) | -21.63% |
| Total Return (5Y CAGR) | -35.89% |
| Return vs SPY (1Y) | -51.64% |
| Max Drawdown (1Y) | -68.09% |
| Max Drawdown (3Y) | -85.62% |
| Sharpe Ratio (1Y) | -0.52 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $2.30 |
| 200-Day Average | $2.80 |
| 52-Week Range | $1.43 to $4.94 |
| RSI (14 Days) | 31.5 |
| Average Volume (20 Days) | 23.79K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.15x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.15x |
|---|---|
| Quick Ratio | 3.15x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| Return on Assets (ROA) | -57.94% |
|---|---|
| ROE (5Y Average) | -44.62% |
| ROA (5Y Average) | -40.28% |
| ROIC (5Y Average) | -41.01% |
Scores
XBIO has an Altman Z-Score of -43.95, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -43.95 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Balance Sheet
| Cash and Equivalents | $5.81M |
|---|---|
| Total Debt | $0 |
| Net Cash | $5.81M |
| Net Cash Per Share | $2.48 |
Balance sheet as of Sep 30, 2026.
Growth
Revenue grew 20.36% a year over 3 years.
| Revenue Growth (3Y CAGR) | +20.36% |
|---|---|
| Revenue Growth (5Y CAGR) | +46.78% |
| Book Value Per Share Growth (2Y CAGR) | -28.83% |
| Tangible Book Per Share Growth (2Y CAGR) | -28.83% |
Stock Splits
The last split was a 1-for-10 reverse split on May 15, 2023.
| Last Split Date | May 15, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Analyst Forecast
Consensus estimates put revenue growth at -20.06% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -20.06% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About XBIO
What is XBIO's market cap?
Xenetic Biosciences has a market cap of $3.49M.
How many shares of XBIO are outstanding?
Xenetic Biosciences has 2.34M shares outstanding. The count is up 51.94% from a year earlier.
Does XBIO pay a dividend?
No. Xenetic Biosciences does not pay a dividend.
How much debt does XBIO have?
Xenetic Biosciences has $0 of total debt and $5.81M of cash and equivalents, a net cash position of $5.81M.
XBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors